TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11881062

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (ARB)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE-I)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both drugs (Candesartan cilexetil and Lisinopril)
Number of subjects: 92
Study: 9781600

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with cisplatin and 5-fluorouracil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 70
Study: 7824815

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation 2 litres/min through a catheter placed in the vestibulum nasi (Group 2a)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation 2 litres/min through a pharyngeal catheter (Group 2b)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation 3 litres/min through a pharyngeal catheter (Group 3)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No oxygen supplementation (Group 1)
Number of subjects: 160
Study: 3043354

Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg bd)
Number of subjects: 193

Group type: COMPARATOR
Intervention: erythromycin ethylsuccinate (1 g bd)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 193

Group type: COMPARATOR
Intervention: erythromycin ethylsuccinate
Number of subjects: 193
Study: 31544377

Group type: EXPERIMENTAL
Intervention: Warm acupuncture at specific acupuncture points (Zhongwan, Qihai, Guanyuan, Zhongji, Guilai, Zigong, Zusanli, Sanyinjiao) for 60 min, once a day, for 5 times with 2 days interval, for 3 consecutive courses until embryo transfer.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Warm acupuncture (as above)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fresh leonurus japonicus capsule, 0.8 g, 3 times a day for 7 days, for 3 courses until embryo transfer.
Number of subjects: 29
Study: 28689295

Group type: EXPERIMENTAL
Intervention: Inhibitory rTMS (1-Hz, 20-min session) applied over the left somatosensory cortex
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 13
Study: 25770704

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sleep Seminar (SS)
Number of subjects: 109
Study: 23648075

Group type: EXPERIMENTAL
Intervention: Intravenous supply of omega-3 PUFAs (EPA and DHA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without omega-3 PUFAs)
Number of subjects: 20
Study: 21614496

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg) twice daily for 3 months followed by CC/HMG/HCG for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 3 months followed by CC/HMG/HCG for 3 months
Number of subjects: 30
Study: 18221256

Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg infusion 2 hours before transplantation and then every 14 days for four more doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tacrolimus-based therapy without daclizumab (historical control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 36
Study: 17722304

Group type: EXPERIMENTAL
Intervention: Topical 10% vitamin C derivative (VC-PMG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical 5% vitamin E
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12923149

Group type: EXPERIMENTAL
Intervention: Hysteroscopic adhesiolysis plus intrauterine application of ACP gel (10 ml)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Operative hysteroscopy alone (control group)
Number of subjects: 92
Study: 10699646

Group type: EXPERIMENTAL
Intervention: Graded vascular autonomic control (head-up tilt at various angles)
Number of subjects: 20
Study: 9123741

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen suppression prior to radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study: 8245333

Group type: EXPERIMENTAL
Intervention: Dipyridamole echocardiography
Number of subjects: 190
Study: 3898846

Group type: EXPERIMENTAL
Intervention: 5 Mu/M2 interferon
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 1 Mu/M2 interferon
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 3 Mu/M2 interferon
Number of subjects: 68
Study: 28988549

Group type: EXPERIMENTAL
Intervention: TAU (treatment as usual) plus low‐intensity CBT‐Music (treatment)
Number of subjects: 28

Group type: COMPARATOR
Intervention: TAU alone (control)
Number of subjects: 28
Study: 24618370

Group type: EXPERIMENTAL
Intervention: UrgoStart® (hydroactive dressing containing nano-oligosaccharide factor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UrgoCell® Contact (neutral foam dressing without NOSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UrgoStart®
Number of subjects: 0

Group type: COMPARATOR
Intervention: UrgoCell® Contact
Number of subjects: 0
Study: 25262251

Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM) with Biotronik ICD (Lumax VR‐T or Lumax DR‐T)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Standard-care follow‐up
Number of subjects: 416
Study: 24645535

Group type: EXPERIMENTAL
Intervention: Class II compression stockings for six months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 80
Study: 20842006

Group type: EXPERIMENTAL
Intervention: 5 needles
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 11 needles
Number of subjects: 36
Study: 18411039

Group type: EXPERIMENTAL
Intervention: Cochrane reviews (drug interventions)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: DARE reviews (drug interventions)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Cochrane reviews (adverse events)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: DARE reviews (adverse events)
Number of subjects: 157
Study: 16151060

Group type: EXPERIMENTAL
Intervention: Palmaz Genesis Peripheral Stent (Cordis)
Number of subjects: 52
Study: 12913326

Group type: EXPERIMENTAL
Intervention: Mixture containing acetyl‐L‐carnitine (ALC), polyunsaturated fatty acids (PUFAs), coenzyme Q10 (CoQ10) and vitamin E
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vitamin E only (control group)
Number of subjects: 14
Study: 10873918

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sequential treatment (adding a selective serotonin reuptake inhibitor)
Number of subjects: 61
Study: 9199588

Group type: EXPERIMENTAL
Intervention: Oral B Ortho toothbrushes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral B Plus 35 toothbrushes
Number of subjects: 20
Study: 1549027

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg, oral dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4077364

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg metoprolol (i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg metoprolol (i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic treatment with slow-release metoprolol (1 X 200 mg/day for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30376962

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (10 mg/kg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 27153745

Group type: EXPERIMENTAL
Intervention: 15 mg E4/DRSP
Number of subjects: 396

Group type: COMPARATOR
Intervention: E2V/DNG (control)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: 20 mg E4/LNG
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: 3.5-3.8% absence of withdrawal bleeding
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: 14.0-18.5% absence of withdrawal bleeding
Number of subjects: 396
Study: 24706588

Group type: EXPERIMENTAL
Intervention: Black raspberry (750 mg/day)
Number of subjects: 77
Study: 22464728

Group type: EXPERIMENTAL
Intervention: Training of affect recognition (TAR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual including occupational therapy (TAU)
Number of subjects: 40
Study: 22166634

Group type: EXPERIMENTAL
Intervention: Tailored loading dosage of clopidogrel
Number of subjects: 205

Group type: COMPARATOR
Intervention: Rational loading dosage of clopidogrel
Number of subjects: 205

Group type: COMPARATOR
Intervention: Talcom group (domestic clopidogrel)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Plavix group
Number of subjects: 205
Study: 18654784

Group type: EXPERIMENTAL
Intervention: Stent-protected angioplasty
Number of subjects: 2973

Group type: COMPARATOR
Intervention: Surgery (carotid endarterectomy)
Number of subjects: 2973
Study: 11286312

Group type: EXPERIMENTAL
Intervention: Extended treatment with dalteparin for 3 months after initial treatment
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Invasive therapy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 9412548

Group type: COMPARATOR
Intervention: Salmeterol 50 micrograms
Number of subjects: 35

Group type: COMPARATOR
Intervention: Albuterol 400 micrograms
Number of subjects: 35
Study: 8501151

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3429872

Group type: EXPERIMENTAL
Intervention: Bendrofluazide (5 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30317262

Group type: EXPERIMENTAL
Intervention: Fixed dose of 10mg of 0.5% hyperbaric bupivacaine (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Height and weight-adjusted dose of 0.5% hyperbaric bupivacaine (Group B)
Number of subjects: 80
Study: 26889801

Group type: EXPERIMENTAL
Intervention: Errorless Goal Management Training (GMT), n=33
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional Goal Management Training (GMT), n=34
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both interventions (Errorless GMT and Conventional GMT)
Number of subjects: 67
Study: 25690005

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Sertraline for 12 weeks
Number of subjects: 251
Study: 23594786

Group type: EXPERIMENTAL
Intervention: Capecitabine-cisplatin plus cetuximab
Number of subjects: 904

Group type: COMPARATOR
Intervention: Capecitabine-cisplatin alone
Number of subjects: 904
Study: 19394599

Group type: EXPERIMENTAL
Intervention: Single lymphocytes from sibling cell lines and blastomeres from sibling day 3 human embryos evaluated using whole genome amplification and single‐nucleotide polymorphism microarrays.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Single‐blastomere DNA fingerprinting technology.
Number of subjects: 6
Study: 18837604

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (group and individual)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 45
Study: 16635073

Group type: EXPERIMENTAL
Intervention: Personalized recruitment letter including information about blood type and donation statistics
Number of subjects: 0

Group type: COMPARATOR
Intervention: General recruitment letter with some general information
Number of subjects: 0
Study: 14613676

Group type: EXPERIMENTAL
Intervention: 5-HT(2) antagonists (clozapine or olanzapine)
Number of subjects: 50
Study: 10969665

Group type: EXPERIMENTAL
Intervention: Video-assisted dissector (group A, n = 31)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Light-coupled retractor (group B, n = 31)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional technique (group C, n = 30)
Number of subjects: 92
Study: 9065277

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 65
Study: 1466849

Group type: EXPERIMENTAL
Intervention: Dapsone (100mg orally twice weekly)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Pentamidine (400 mg nebulized monthly)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 98

Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 98
Study: 31535100

Group type: EXPERIMENTAL
Intervention: 11-mm-long implants combined with maxillary sinus floor elevation
Number of subjects: 38

Group type: COMPARATOR
Intervention: 6-mm-long implants without any grafting
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 28522762

Group type: EXPERIMENTAL
Intervention: Postmeal exercise with metformin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metformin/sedentary
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metformin/exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Washout/sedentary
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Washout/exercise
Number of subjects: 10
Study: 27235761

Group type: EXPERIMENTAL
Intervention: Group Reminiscence Approach - Reality Orientation (GRA-RO)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Physical Activity
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cognitive Training
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: GRA-RO
Number of subjects: 94
Study: 24464385

Group type: EXPERIMENTAL
Intervention: Transvaginal video‐assisted cholecystectomy (TVC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 97
Study: 23020699

Group type: EXPERIMENTAL
Intervention: Single-use polyvinyl chloride laryngeal mask airway
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single-use silicone laryngeal mask airway
Number of subjects: 72
Study: 19755082

Group type: EXPERIMENTAL
Intervention: Steel scalpel incision
Number of subjects: 19

Group type: COMPARATOR
Intervention: Electrocautery blade incision
Number of subjects: 19
Study: 18675519

Group type: EXPERIMENTAL
Intervention: Imipramine (1mg/kg daily, max 100mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoxetine (5mg for >40kg, 10mg for 40-60kg, 20mg for >60kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15970897

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (ethinyl estradiol [EE] 20 microg/d and norelgestromin 150 microg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral contraceptive (EE 35 mug and norgestimate 250 microg)
Number of subjects: 24
Study: 12878917

Group type: EXPERIMENTAL
Intervention: Naltrexone and acamprosate (16 weeks of active treatment)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Medical Management (9 brief sessions)
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (up to 20 sessions)
Number of subjects: 1375

Group type: COMPARATOR
Intervention: No-pill psychotherapy-alone condition
Number of subjects: 1375
Study: 10474019

Group type: EXPERIMENTAL
Intervention: 600 mg/day ipriflavone
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.8 g/day calcium lactate
Number of subjects: 60
Study: 8695365

Group type: EXPERIMENTAL
Intervention: Gemcitabine administered as a 24 h infusion at a maximum tolerated dose (MTD) of 180 mg m‐2 on days 0, 7, and 14, repeated every 28 days.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gemcitabine administered as a 24 h infusion at various dose levels (10, 20, 40, 80, 120, 180, and 210 mg m‐2).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose of gemcitabine.
Number of subjects: 24
Study: 1878329

Group type: EXPERIMENTAL
Intervention: 2% solution of mineralizing agent and 0.2% NaF solution
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo and 0.2% NaF solutions
Number of subjects: 123
Study: 6346847

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31665070

Group type: EXPERIMENTAL
Intervention: CHO-WP-MPH (marine protein hydrolysate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CHO-WP (whey protein and carbohydrate)
Number of subjects: 14
Study: 29020831

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site surgery (LESS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Minilaparoscopy (ML)
Number of subjects: 60
Study: 27497840

Group type: EXPERIMENTAL
Intervention: EX/RP (Exposure and Response Prevention)
Number of subjects: 37
Study: 23881116

Group type: EXPERIMENTAL
Intervention: Structured training group (SG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flexible training group (FG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Heart-rate recovery in FG
Number of subjects: 15

Group type: COMPARATOR
Intervention: Heart-rate recovery in SG
Number of subjects: 15
Study: 22518835

Group type: EXPERIMENTAL
Intervention: 30%‐3
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 80%‐1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 80%‐3
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 80%‐1 and 80%‐3
Number of subjects: 18
Study: 19789191

Group type: EXPERIMENTAL
Intervention: Intravenous low dose dexamethasone (4 mg initial dose, followed by 2 mg every 8 hours for 24 hours)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 200
Study: 17553993

Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal DLPFC tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left anodal/right cathodal DLPFC tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unilateral DLPFC stimulation (anodal tDCS over right or left DLPFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral DLPFC tDCS (both anodal and cathodal)
Number of subjects: 0
Study: 15036491

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) treatment for 12 or 14 days with combinations of 1 mg or 2 mg E2V and 2.5 mg or 5 mg MPA.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (younger women under 60 years)
Number of subjects: 46
Study: 11485531

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (119 patients)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Total parenteral nutrition (122 patients)
Number of subjects: 241
Study: 9727762

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 88
Study: 8047805

Group type: EXPERIMENTAL
Intervention: Pivmecillinam, 50 mg/kg.day for 5 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nalidixic acid, 60 mg/kg.day for 5 days
Number of subjects: 80
Study: 3196080

Group type: EXPERIMENTAL
Intervention: Diet high in polyunsaturated fatty acids supplemented with eicosapentaenoic and docosahexaenoic acids
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet high in saturated fatty acids
Number of subjects: 12
Study: 31974914

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-eradication
Number of subjects: 32
Study: 30106530

Group type: EXPERIMENTAL
Intervention: Two-step 0.454% SnF₂ dentifrice and 3% H₂O₂ gel sequence
Number of subjects: 49

Group type: COMPARATOR
Intervention: Regular anticavity toothpaste control
Number of subjects: 49
Study: 28942806

Group type: EXPERIMENTAL
Intervention: Stepped care (low intensity, standard CBT, individually tailored treatment)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Single, empirically validated cognitive-behavioral therapy (CBT) program
Number of subjects: 281
Study: 26299236

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 304

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 304
Study: 23589527

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion at 0.2 nmol kg(‐1) h(‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion at 0.6 nmol kg(‐1) h(‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 16
Study: 21248722

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 18088076

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (Aricept)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Open donepezil treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17315802

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dakin's liquid + urea peroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dakin's liquid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 1% and 2%
Number of subjects: 0
Study: 12798838

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MDC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: MDC
Number of subjects: 98
Study: 10556657

Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis patients
Number of subjects: 18
Study: 8740617

Group type: EXPERIMENTAL
Intervention: Training group, provided with a self‐instructional booklet of pain control techniques
Number of subjects: 48

Group type: COMPARATOR
Intervention: Citizenship group, to control for reading a booklet
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group with no advanced preparation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Warning time of 180 sec
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High scorers on perceived self‐efficacy
Number of subjects: 48
Study: 1907422

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous nitroglycerin (33 micrograms/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-dose intravenous nitroglycerin (133 micrograms/min)
Number of subjects: 16
Study: 6615094

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 106
Study: 31063550

Group type: EXPERIMENTAL
Intervention: Opioid users (OU)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Methadone-maintained smokers
Number of subjects: 129